AZ, Takeda, Novartis Praised For Medicines Access Work But More Is Needed
The 20 major companies in the Access to Medicines Index have made progress in areas like inclusive business models, R&D prioritization and equitable pricing, but not enough is being done to develop new medicines for less profitable diseases or to support flexibilities such as compulsory licensing, says a new report from the Access to Medicine Foundation.
You may also be interested in...
The Medicines Patent Pool has developed a new prioritization framework to identify promising drug candidates for in-licensing, including in the antibiotics area, after its scope was expanded beyond its initial target areas. Later this year it also plans to look at whether its licensing model could be adapted to biologic medicines.
Efforts are under way in the UK on many fronts to develop new treatments and vaccines for coronavirus infection, including researching new uses of existing products and clinical trials of new vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.